Press Detail

/
PRESS RELEASE

Biotest increases EBT significantly by 26%

- EBIT increase by 9.0%

- Bivigam^TM - 'Complete Response Letter' sent to FDA

- Long term Agreement closed with ViroPharma, USA

Dreieich, 13. November 2012. During the first nine months of 2012, the Biotest Group was able to increase its revenue by 4.2% compared with sales from Continuing Operations in the same period of 2011. Thus, the Group generated revenue of EUR324.9 million compared with EUR311.9 million in the previous year.

The international markets were the main driving force behind the increase in revenue of the Group. While business in Europe suffered stagnation caused by continuing cost pressures as well as the Euro and debt crisis, revenue outside of Europe increased substantially in some countries.

Earnings before interest and taxes (EBIT) also rose strongly in the reporting period. EBIT of EUR32.8 million was recorded compared with EUR30.1 million in the first nine months of 2011. This represents an increase of 9.0%. The Therapy segment made the major contribution to this development. In this area, earnings rose by 20.7% compared to the preceding period. In line with this development, the EBIT margin rose from 9.7% to 10.1%.

The financial result was improved substantially during the first nine months of 2012 and totalled -EUR7.3 million after -EUR9.9 million in the previous year period. The financial result made a particular improvement in the third quarter 2012, up by 56.3% year-on-year. The main reason for this is the downward adjustment made in the previous year period to the book value of Greek government bonds, which impacted the financial result by a disproportionately high amount. In the first quarter 2012 Biotest had sold all remaining Greek bonds.

For the Biotest Group, this resulted in earnings before tax (EBT) of
EUR25.5 million. EBT were therefore 26.2% up on the figure posted in the same period in 2011 totalling EUR20.2 million. Due to substantially increased tax expenses, which resulted from the non-valuation for tax purposes of the Greek subsidiary's losses and start-up losses at the Brazilian subsidiary, earnings after tax (EAT) rose only moderately from EUR14.6 million to EUR15.6 million. Overall, earnings per share on Continuing Operations therefore amounted to EUR1.33. This figure was EUR1.25 for the first nine months of 2011.

In August, Biotest received new information regarding the authorisation of Bivigam(TM) on the US market from the US Food and Drug Administration (FDA). The FDA requested a new and additional validated test system for detection of thrombogenic activity - the first time this has been requested for an initial approval. This assay should be used for batch release testing of Bivigam^TM. Here, Biotest has joined forces with a renowned lab, which collaborates closely with the FDA. Meanwhile, the test validation has been completed and the corresponding data was sent to the FDA in a 'Complete Response Letter' by the end of October.

Further progress was achieved for various development projects in the first nine months of the current financial year.

After the end of the reporting period, Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG, expanded its contractual cooperation with ViroPharma Biologics, Inc. (ViroPharma) in the USA. As part of the deal, BPC will sell increasing volumes of blood plasma to ViroPharma in the coming three years. As part of the long-term agreement with BPC, which initially runs until the end of 2017, ViroPharma is obliged to buy plasma with a total value of around USD 70 million over the next two years.

In addition, as part of a European decentralised procedure (DCP), Biotest received the approval for the 10% intravenous immunoglobulin solution Intratect (100 g/l) at the end of October. Intratect 10% was specifically created for patients, who are able to tolerate a 10% solution and for whom time saving is a decisive factor.

Outlook:
There is an encouraging growth in business despite the delay in the approval of Bivigam(TM) and caution regarding the valuation of current debts in Greece. Biotest is therefore confirming the forecast of a 3 to 5% rise in revenue with slightly higher operating earnings (EBIT) than the previous year (EUR41.6 million) stated in the annual report 2011. This assumes that economic conditions will remain stable in our target markets.

The nine-month report is available on the company's website http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_reports.cfm.The presentation for today's conference for analysts and journalists as well as an audio file is available for download from the website.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein portfolio Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest also researches into the development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart